 |
 |
 |
 |
|
 |
 |
для выведения нейролептиков неэффективны.
Литература
Механизм действия
Hyman SE, Nestler EJ. Molecular foundations of psychiatry. Washington, DC: American Psychiatric
Press, 1993.
Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor
occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286.
Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on
PET-measured D2 and 5-HT
2A
receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869.
Tamminga CA. Principles of the pharmacotherapy of schizophrenia. In: Charney DS, Nestler EJ,
Bunnery BS, eds. Neurobiology of mental illness. New York: Oxford University Press, 1999.
Шизофрения и шизоаффективное расстройство
American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia.
Am J Psychiatry 1997; 154 (4 suppl).
Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms
in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20.
Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic
implications. Biol Psychiatry 1999; 46:1388.
Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-refractory schizophrenic: a double-
blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789.
Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46:1396.
Harder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;
151:825.
Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of treatment response from a first episode of
schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156:544.
Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-
dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549.
Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of
schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Am J Psychiatry 1997; 154:457.
Viguera AC, Baldessarini RJ, Hegarty JM, et al. Clinical risk following abrupt and gradual withdrawal
of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54:49.
Аффективные расстройства
Tohen M, Sanger TM, McElroy SL, et al. Olanzepine versus placebo in the treatment of acute mania.
Am J Psychiatry 1999; 156:702.
Zarate СA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;
56:411.
Другие психические и неврологические расстройства
Goldberg SC, Schulz С, Schulz PM, et al. Borderline and schizotypal personality disorders treated with
low-dose thiothixene vs. placebo. Arch Gen Psychiatry 1986; 43:680.
Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;
5:239.
Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide, and placebo for the
treatment of Gilles de la Tourette syndrome. Arch Gen Psychiatry 1989; 46:722.
Атипичные антипсихотики
